Double trouble for prostate cancer: synergistic action of AR blockade and PARPi in non-HRR mutated patients.

Giesen, Alexander; Baekelandt, Loïc; Devlies, Wout; Devos, Gaëtan; Dumez, Herlinde; Everaerts, Wouter; Claessens, Frank; Joniau, Steven

Giesen, Alexander; Baekelandt, Loïc; Devlies, Wout; Devos, Gaëtan; Dumez, Herlinde; Everaerts, Wouter; Claessens, Frank; Joniau, Steven.

Afiliación

Giesen A; Department of Urology, University Hospitals Leuven, Leuven, Belgium.
Baekelandt L; Department of Urology, University Hospitals Leuven, Leuven, Belgium.
Devlies W; Department of Urology, University Hospitals Leuven, Leuven, Belgium.
Devos G; Departments of Cellular and Molecular Medicine and Clinical and Experimental Medicine, Catholic University Leuven (KU Leuven), Leuven, Belgium.
Dumez H; Department of Urology, University Hospitals Leuven, Leuven, Belgium.
Everaerts W; Department of Oncology, University Hospitals Leuven, Leuven, Belgium.
Claessens F; Department of Urology, University Hospitals Leuven, Leuven, Belgium.
Joniau S; Departments of Cellular and Molecular Medicine and Clinical and Experimental Medicine, Catholic University Leuven (KU Leuven), Leuven, Belgium.

Front Oncol ; 13: 1265812, 2023.

Article en En | MEDLINE | ID: mdl-37810962

Palabras clave

HRR genes; PARP inhibition (PARPi); androgen receptor signaling inhibitor; prostate cancer; synergistic effect (combined treatment)

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Front Oncol Año: 2023 Tipo del documento: Article País de afiliación: Bélgica Pais de publicación: Suiza

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google